Quotient Limited logo
Quotient Limited QTNT
report update icon

Quarterly report 2023-Q3
added 05-23-2026

Quotient Limited Income Statement 2022-2011 | QTNT

Brief overview of revenue and earnings at Quotient Limited

The overview follows changes across a five-year period. Revenue at Quotient Limited moved from 22.2 million dollars in 2017 to 38.5 million dollars in 2022. Overall revenue changed by +73.3%, equal to an annualized rate of about 11.6%. The pace indicates confident and sustained business growth.

The five-year change in gross profit reached +31.3%: from 11.4 million dollars to 14.9 million dollars. Direct costs outpaced revenue, limiting the benefit of changes in sales. At the margin level, the figure shifted from 51.2% to 38.8%. The business retained less gross profit from each unit of revenue.

EBITDA was −64.7 million dollars at the beginning and −96.6 million dollars at the end of the period (−49.4%). Operating performance weakened relative to revenue. EBITDA margin was −291% at the start and −250.9% at the end. The business generated more EBITDA from each unit of revenue.

Net income moved from −$85.1 million at the start to −$125 million at the end. Larger losses indicate rising pressure on the business.

What the figures show

The indicators point to a weaker financial profile. The positive side is supported by positive operating leverage and revenue expansion. The most visible risks are pressure from direct costs, a weaker final result and a low EBITDA margin. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Quotient Limited

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 237 M 526 M 522 M 250 M 139 M 94.7 M 236 M 3.36 M - - -

Shares

102 M 91.6 M 101 M 54.9 M 40.8 M 28.1 M 19.6 M 14.8 M 187 K 74.9 K - -

Historical Prices

2.59 5.21 9.51 6.12 4.95 4.84 16 18 - - -

Net Income

-125 M -111 M -31.7 M -106 M -82.3 M -85.1 M -33.9 M -59.1 M -10.2 M -4.71 M -4.47 M -4.62 M

Revenue

38.5 M 43.4 M 32.7 M 29.1 M 24.7 M 22.2 M 18.5 M 18.4 M 19.8 M 14.4 M 12.2 M 10 M

Cost of Revenue

23.6 M 20.1 M 4.97 M 17.2 M 10.5 M 10.8 M 9.66 M 9.76 M 8.41 M 7.17 M - -

Gross Profit

14.9 M 23.3 M 3.78 M 11.9 M 14.3 M 11.4 M 8.86 M 8.64 M 11.3 M 7.2 M 5.47 M 4.41 M

Operating Income

-104 M -82.7 M -21.6 M -79.2 M -70 M -74.1 M -49.1 M -29.7 M -8.89 M -4.49 M - -

Interest Expense

11.6 M 2.72 M 617 K -6.94 M 2.37 M -1.11 M 3.5 M -4.06 M -197 K 11 K - -

EBITDA

-96.6 M -73.9 M -9.13 M -66.5 M -59.7 M -64.7 M -46.2 M -28.5 M -8.37 M -4.15 M -2.98 M -3.12 M

Operating Expenses

119 M 106 M 25.4 M 91.1 M 84.2 M 85.4 M 58 M 38.4 M 20.2 M 11.7 M 9.43 M 8.5 M

General and Administrative Expenses

42.1 M 37.4 M 7.52 M 26.6 M 21.5 M 18.5 M 24.1 M 15.3 M 8.54 M 6.35 M 6.01 M 5.35 M

All numbers in USD currency

Quarterly Income Statement Quotient Limited

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

4.25 M 4.25 M 105 M 4.25 M 102 M 102 M 101 M 2.55 M 101 M 83.9 M 80.5 M 101 M 73.8 M 66.3 M 66.1 M 73.8 M 56.6 M 52.1 M 45.8 M 56.6 M 56.6 M 52.1 M 45.6 M 43.4 M 43.4 M 37.7 M 36.8 M 29.5 M 20.4 M 17.4 M 17 M 20.4 M 15.1 M 14.4 M 12.8 M 15.1 M 14.4 M 12.8 M 342 K 829 K 144 K 237 K - - - - - - - - -

Net Income

-13.3 M -45.9 M -38.9 M -13.3 M -44.8 M -27.1 M -27.3 M -44.8 M -29.8 M -15 M -25.4 M -31.7 M -27.5 M -27 M -23.6 M -27.5 M -26.3 M -27.4 M -25.2 M -26.3 M -26.3 M -27.4 M - -20.3 M -20.3 M -21.7 M -20.2 M -31.2 M -9.78 M -4.43 M -10.2 M -9.78 M -42.3 M -11.7 M -2.62 M -42.3 M -56.6 M -14.3 M - -3.27 M -4.95 M -1.68 M - - - - - - - - -

Revenue

9.95 M 8.86 M 8.81 M 9.95 M 10.2 M 9.47 M 9.09 M 10.2 M 8.75 M 16.1 M 8.92 M 8.75 M 7.94 M 7.85 M 8.17 M 7.94 M 6.72 M 6.25 M 7.88 M 6.72 M 6.72 M 6.25 M - 5.86 M 5.86 M 5.91 M 6.83 M 4.84 M 4.35 M 4.27 M 4.85 M 4.35 M 4.06 M 4.53 M 5.92 M 4.06 M 14.5 M 10.4 M - 3.91 M 15.1 M 11.2 M - - - - - - - - -

Cost of Revenue

3.9 M 21.1 M 6.12 M 3.9 M 7.93 M 4.88 M 4.78 M 7.93 M 4.97 M 4.5 M 5.41 M 4.97 M 4.53 M 3.97 M 4.56 M 4.53 M 4.19 M 4.55 M 4.06 M 4.19 M 4.19 M 4.55 M - 2.32 M 2.32 M 2.79 M 2.83 M 2.6 M 2.22 M 2.12 M 2.75 M 2.22 M 2.2 M 2.71 M 2.45 M 2.2 M 7.36 M 5.16 M - 1.94 M 6.27 M 4.33 M - - - - - - - - -

Gross Profit

6.05 M -12.3 M 2.69 M 6.05 M 2.24 M 4.59 M 4.31 M 2.24 M 3.78 M 11.6 M 3.51 M 3.78 M 3.41 M 3.88 M 3.61 M 3.41 M 2.54 M 1.7 M 3.82 M 2.54 M 2.54 M 1.7 M - 3.53 M 3.53 M 3.12 M 3.99 M 2.24 M 2.13 M 2.15 M 2.1 M 2.13 M 1.86 M 1.82 M 3.47 M 1.86 M 7.14 M 5.29 M - 1.97 M 8.83 M 6.86 M - - - - - - - - -

Operating Income

-25.6 M -37.7 M -25.8 M -25.6 M -31.3 M -23.8 M -21.9 M -31.3 M -21.7 M -13.1 M -19.7 M -21.6 M -22.4 M -18.4 M -18.4 M -22.4 M -19 M -21.1 M -18.5 M -19 M -19 M -21.1 M - -17.1 M -17.1 M -18.1 M -16.9 M -22.4 M -12.8 M -13 M -10.5 M -12.8 M -7.33 M -8.22 M -4.41 M -7.33 M -20 M -12.6 M - -2.8 M -4.29 M -1.49 M - - - - - - - - -

Interest Expense

20.6 M -15.2 M -4.37 M 20.6 M -3.51 M 5.92 M 9.5 M -3.51 M 192 K 5 M 233 K 617 K 1.89 M -1.24 M 952 K 1.89 M -1.54 M -468 K -3.51 M -1.54 M -1.54 M -468 K - 33 K 33 K 565 K 880 K -4.57 M 305 K -657 K -635 K 305 K 130 K -2.96 M 534 K 130 K -1.49 M 534 K - -45 K -83 K 77 K - - - - - - - - -

EBITDA

-25.6 M -37.7 M -25.8 M -25.6 M -31.3 M -23.8 M -21.9 M -31.3 M -19.4 M -10.9 M -17.8 M -19.2 M -13.4 M -12.4 M -15.4 M -19.5 M -9.52 M -14.6 M -15.2 M -16 M -9.52 M -14.6 M - -14.5 M -9.42 M -13 M -14.4 M -20.1 M -11.2 M -12.1 M -10.1 M -12.1 M -6.39 M -7.62 M -4.12 M -7.01 M -19 M -12.3 M - -2.8 M -3.91 M -1.25 M - - - - - - - - -

Operating Expenses

31.6 M 25.5 M 28.5 M 31.6 M 33.5 M 28.4 M 26.2 M 33.5 M 25.5 M 24.7 M 23.2 M 25.4 M 25.8 M 22.3 M 22 M 25.8 M 21.6 M 22.8 M 22.4 M 21.6 M 21.6 M 22.8 M - 20.6 M 20.6 M 21.2 M 20.9 M 24.7 M 14.9 M 15.1 M 12.6 M 14.9 M 9.18 M 10 M 7.87 M 9.18 M 27.1 M 17.9 M - 4.77 M 13.1 M 8.35 M - - - - - - - - -

General and Administrative Expenses

11.5 M 7.66 M 9.4 M 11.5 M 15 M 8.62 M 8.35 M 15 M 7.52 M 8.23 M 8.58 M 7.52 M 8.12 M 5.98 M 6.62 M 8.12 M 6.47 M 6.76 M 6.16 M 6.47 M 6.47 M 6.76 M - 5.8 M 5.8 M 4.79 M 5.26 M 4.54 M 6.49 M 5.49 M 4.79 M 6.49 M 3.64 M 3.72 M 3.26 M 3.64 M 10.6 M 6.98 M - 1.96 M 5.44 M 3.49 M - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Quotient Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
$ 11.73 -1.26 % $ 1.05 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 16.5 -1.02 % $ 695 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.22 -0.31 % $ 26.1 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Exagen Exagen
XGN
$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 178.18 -1.14 % $ 14 B irlandaIrlanda
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA